



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Andrology, Vol 14, Issue 6 407-410, Copyright © 1993 by The American Society of Andrology

JOURNAL ARTICLE

Treatment of idiopathic erectile dysfunction in men with the opiate antagonist naltrexone--a double-blind study

W. Brennemann, B. Stitz, H. Van Ahlen, K. A. Brensing and D. Klingmuller

Department of Clinical Biochemistry, University of Bonn, Germany.

Opiate antagonists can indirectly stimulate the secretion of luteinizing hormone (LH) and testosterone, as well as sexual functions in animals and humans. We therefore treated 20 otherwise healthy men with idiopathic erectile dysfunction aged 46.3 +/- 2.7 years (mean +/- SE, range 23.9-63.3) in a double-blind study with an opiate antagonist, naltrexone, or placebo. The erectile dysfunction of these

This Article

- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted

Services

- ▶ Similar articles in this journal
- ▶ Similar articles in PubMed
- Alert me to new issues of the journal
- ▶ Download to citation manager

Citing Articles

- ▶ Citing Articles via HighWire
- Liting Articles via Google Scholar

Google Scholar

- Articles by Brennemann, W.
- Articles by Klingmuller, D.
- ▶ Search for Related Content

PubMed

- ▶ <u>PubMed Citation</u>
- Articles by Brennemann, W.
- Articles by Klingmuller, D.

men had persisted for 3.6 +/- 0.5 years despite libido maintenance; standard procedures had excluded any organic causes. Trial duration was 12 weeks overall. After a 4-week forerun, the patients received at first 25 mg naltrexone/day orally or placebo for 4 weeks followed by 4 weeks of a 50-mg dose of naltrexone/day or placebo. Each day the patients filled out a questionnaire detailing libido, degree of erection, frequency of sexual intercourse, and spontaneous morning erections. Serum concentrations of gonadotropins and testosterone were determined radioimmunologically in the initial stage and at the end of each phase. Both patient collectives had similar initial factors. The group treated with naltrexone showed a significant rise in spontaneous early morning erections during the treatment: from 2.8 +/- 0.3 to 4.2 +/- 0.3 a week (P < 0.001). The placebo group showed no significant change in spontaneous erections (2.4 +/- 0.3 and 2.6 +/- 0.3, respectively). The subjective parameters, however, such as libido, degree of erection, and frequency of sexual intercourse showed no significant difference within each group. There was no difference in LH, follicle-stimulating hormone, or testosterone concentrations in both groups. Thus, treatment with naltrexone significantly raises the rate of spontaneous early morning erections when compared to controls. (ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:



ENDOCRINE REVIEWS

HOME

F. R. Kandeel, V. K. T. Koussa, and R. S. Swerdloff Male Sexual Function and Its Disorders: Physiology, Pathophysiology, Clinical Investigation, and Treatment Endocr. Rev., June 1, 2001; 22(3): 342 - 388.

[Abstract] [Full Text] [PDF]

ARCHIVES GINEAL PROBLEM

ARCHIVES OF GENERAL PSYCHIATRY

►HOME

C. M. Meston and P. F. Frohlich
The Neurobiology of Sexual Function
Arch Gen Psychiatry, November 1, 2000; 57(11): 1012 - 1030.
[Abstract] [Full Text] [PDF]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Copyright © 1993 by The American Society of Andrology.